Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes
Kutz A, Kim D,Wexler D, Liu J, Schneeweiss S, Glynn R and Patorno E
Diabetes Care 2023;46(11):2004–2014
https://doi.org/10.2337/dc23-0671